exhibiting extensive crosstalk and some redundancy. It has long been viewed that SREBP2 is primarily responsible for activation of genes involved in cholesterol synthesis, as opposed to fatty acid synthesis.
In contrast, SREBP1c functions primarily in the liver to drive fatty acid synthesis, while SREBP1a can drive both pathways in all tissues. However, understanding the tissue-specific, and differential genetic requirements for each SREBP has proven elusive. In this issue of the Journal, Vergnes et al. from the laboratory of Karen Reue confirm the role of SREBP2 in regulating cholesterol biosynthesis genes, but discover that SREBP2 has an unanticipated function in survival and limb patterning during development and that it also possesses an important role for fatty acid synthesis via compensatory up-regulation of SREBP1 genes [1] .
Vergnes et al. use a gene trap allele of murine Srebf2 to examine deficiency of Srebp2 in embryos and adult animals, at various dosages through an ingenious conditional allele. This conditional allele is a genetic modification of Srebf2 through a gene trap, which is an insertional mutation, usually in an intron, that contains a strong splice acceptor and polyadenylation signal that disrupts splicing, resulting in a severely truncated protein product. The novelty of this gene trap, within the first intron of Srebf2, is that it enables the conversion of a null allele to a hypomorphic (reduced function) allele through Cre-Lox recombination. This is due to the nature of this specific gene trap, in which the splice acceptor is flanked by loxP sites, followed by the β-GEO fusion protein/reporter. Srebf2 splicing with this gene trap and other important genes are less likely to be affected unintentionally. This is especially important because engineered mutations could affect the Srebf2-embedded microRNA gene, miR-33, which represses Srebp1 and cellular cholesterol efflux 33 [3] .
Using the fully trapped null allele, Vergnes et al. document the lethal embryonic phenotype caused by loss of Srebp2, importantly, with no effect on miR-33 expression caused by a lack of Srebp2. The critical importance of Srebf2 is perhaps not too surprising given the embryonic lethal phenotype of engineered
Srebf2
-/-mouse knockouts that was noted, although not described, more than 18 years ago [4] . This early lethality is likely due to the widespread expression of Srebp2 in the developing embryo described by Vergnes et al., and its known role in cholesterol synthesis. However, the cause of embryonic lethality remains unknown along with a gender dimorphism where ~50% female Srebf2 -/hyp mice died between 8
and 12 weeks of age.
Surprisingly, the effect of Srebp2 deficiency on fatty acid synthesis genes was just as severe as the effect on cholesterol biosynthesis genes. In whole Srebf2 -/-embryos, transcript levels of Srebp1a and Srebp1c
(from the Srebpf1 locus) were dramatically reduced, which may be responsible for depletion of fatty acid synthesis genes. This effect was also observed in the liver of a sole surviving Srebf2 -/-adult animal. it is reasonable to propose that compensation may be provided by maternally-supplied HDL and LDL, via placental transport, and/or by other undefined basal transcriptional activation of cholesterol synthesis genes. Regardless, the findings here are a testament to the robustness of cholesterol and fatty acid synthesis, which can maintain reasonable levels of these essential molecules in the near absence of three master regulators (SREBPs).
Lastly, Vergnes et al. found limb patterning defects in Srebf2
-/-embryos that may reflect altered signaling of the critical "morphogen" Hedgehog (Hh). Hh proteins are secreted signaling proteins that are unusual in that they undergo post-translational modification in the form of cholesterylation and palmitylation [5, 6] , which have been reported to modulate Hh diffusion throughout tissues during development (forming a so-called morphogen gradient) [7] . While whole embryo cholesterol levels were not changed in Srebf2 
